Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3811 in healthy volunteers
NCT05740475Phase 1Completed
- Sponsor
- Mabwell
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary fibrosis (PF) comparing 9MW3811 injection with Placebo (2 arms). Primary endpoints: Adverse Events at 113 days, Physical Examination Abnormalities at 113 days and 3 more. Started Mar 2023; status: completed.
02
Drugs
9MW3811
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05740475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740475.